SWK
48
3
ADI
54
3
GE
64
6
KMI
77
4
NVDA
56
4
PYPL
33
8
FMC
37
3
ZBH
65
3
DAL
28
6
RCL
66
2
ZION
55
7
DNB
60
2
XRAY
17
4
PFG
52
7
UNH
48
3
URI
42
-4
HCA
57
6
EOG
39
3
CAT
48
2
ACN
29
-4
SWK
48
3
ADI
54
3
GE
64
6
KMI
77
4
NVDA
56
4
PYPL
33
8
FMC
37
3
ZBH
65
3
DAL
28
6
RCL
66
2
ZION
55
7
DNB
60
2
XRAY
17
4
PFG
52
7
UNH
48
3
URI
42
-4
HCA
57
6
EOG
39
3
CAT
48
2
ACN
29
-4
Financhill
Back

Axsome Therapeutics 10K Form

Buy
54

AXSM
Axsome Therapeutics

Last Price:
$121.95
Seasonality Move:
13.74%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AXSM News And Ratings

See the #1 stock for the next 7 days that we like better than AXSM

AXSM Financial Statistics

Sales & Book Value

Annual Sales: $385.7M
Cash Flow: $-26.2M
Price / Cash Flow: 0
Annual Sales: $1.17
Price / Book: 104.27

Profitability

EPS (TTM): -5.99000
Net Income (TTM): $-287.2M
Gross Margin: $352.4M
Return on Equity: -244.32%
Return on Assets: -51.07%

Axsome Therapeutics Earnings Forecast

Key Axsome Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for AXSM is 91.37%.
  • The Selling, General & Administrative Expenses for AXSM have been equal to 106.65% of Gross Profit Margin.
  • The Research & Development expenses have been 48.50% of Revenue.
  • The Net Earning history of AXSM is -74.47% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 2 years.

Axsome Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: AXSM
CUSIP: 05464T
Website: axsome.com

Debt

Debt-to-Equity Ratio: 3.17
Current Ratio: 2.11
Quick Ratio: 1.99

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 72.85

AXSM Technical Analysis vs Fundamental Analysis

Buy
54
Axsome Therapeutics (AXSM) is a Buy

Is Axsome Therapeutics a Buy or a Sell?